Skip to main content

JSW Steel

An equity analyst tracking metals and steel sector cautions against the bullish reports being published by a couple of bro-kerage houses for JSW Steel. No doubt this leading steel com-pany is well managed, but the analyst opines that the steel in-dustry is still facing several challenges globally, and it may take several years to recover. In these circumstances, the chances ofthe scrip crossing Rs. 1200-mark appear to be remote. Little wonder, in the second quarter of FY 16, the company’s saleshave come down by 21.5 per cent to Rs. 10,743 crore as com-
pared to Rs. 13,692 crore in the corresponding quarter last year and the profit at net level has nosedived from Rs 749 crore to Rs 118 crore, a drop of 84.2 per cent. The second quarter results would have been worse but for the good show by a couple of overseas subsidiaries. The disastrous economic meltdown in China will not allow the steel industry to stage a recovery for 6 to & quarters, it is widely believed. The JSW stock price will hover between Rs. 800 and Rs. 1000, the analyst insists.

Comments

Post a Comment

Popular posts from this blog

Best Buy For Monday Upper Circuit Expected TCI FINANCE

*Intraday & Short Term News For Monday* *Fii And Dii News*   *TCI FINANCE LTD (501242 & NSE) (31)*   Incorporated in 1973, TCI Finance Ltd (TCIFL) is a Non-Banking Finance Company (NBFC) registered with the RBI and engaged in the business of Inter-Corporate Deposits, investment in equities of bodies corporate etc.   The Company was promoted by Mr. Mahendra Agarwal, who is also the Managing Director and CEO of Gati Ltd, a pioneer in express distribution and supply chain and promoted by TCFIL   The Rs.2 paid-up share of Gati Ltd currently trades at Rs.113. TCIFL has one subsidiary - ITAG Business Solutions Ltd engaged in the business of Knowledge Process Outsourcing (KPO) in the domain of Intellectual Property Services.   *It is co-promoter of GATI LTD. Company is holding 55,12,455 shares (5.09%) stake in GATI LTD. At CMP value of investments is around Rs.62.3crore. Equity is Rs.12.87crore. Thus value of investment works out to Rs.48.4 per share ...
1 comment
Read more

Danlaw Technologies India Ltd: For multi-bagger gains (BSE Code: 532329) (CMP: Rs. 60.75) (FV: Rs.10)

The earnings season so far has been weak and worries over domestic growth continue to weigh on the market sentiment which has led the markets back on the downward path.. A value investor, however, need not worry about the broad markets as value stocks perform better and post good results. One such value-pick is Danlaw Technologies India Ltd. (DTIL). Company background: DTIL is the offshore technology and product development center of its parent company - Danlaw Incorporated, founded by Mr. Raju Dandu and Mr. Lloyd Lawrence in Michigan, USA in 1984. DTIL’s mission is to provide high quality services and products in Automotive Electronics, develop R&D driven Signal Processing technologies for communication and control, configure solutions and provide exceptional Information Technology (IT) services in the areas of education, health, banking and e-governance and provide world-class products and solutions for secured access through biometric access control technologies with intellige...
1 comment
Read more

Some Opportunities Are left in Pharma Sector

Torrent Pharmaceuticals  reported impressive 75% growth in revenues and profit in the first quarter of FY 2016. The sterling performance was driven by the launch of new product in the US market, which has limited competition at present. The focus is on the therapeutic segments of cardiovascular and CNS. There is presence in gastro-intestinal, diabetology, anti-infective, pain management, nephrology, oncology, gynecology and pediatric segments as well. The manufacturing plants for formulations and bulk drugs have been approved by authorities of several regulated and semi-regulated markets such as the US, the UK, Brazil, Germany, Australia and South Africa. Capacity will increase almost 100% once the new plant at Dahej in Gujarat becomes operational. The plant will be one of the largest pharmaceuticals manufacturing facilities in the country at a single location. The unit will primarily cater to the key regulated markets of the US and Europe. Approval from regulators such...
Post a Comment
Read more